Imaging Biometrics (LSE:IBAI) said its US subsidiary, Imaging Biometrics, has signed an annual subscription agreement with a leading regional health system for its quantitative neuro-oncology imaging software.
The London-listed company's platform, which includes IB Neuro, IB Delta T1 and IB FTBx, converts routine MRI scans into standardized, objective biomarkers of tumor biology, replacing the subjective interpretation typical of conventional imaging workflows.
The healthcare organisation is among the first in its region to offer these quantitative MRI tools to support neuro-oncology treatment decisions.
"By standardizing the assessment of tumor physiology and treatment response, our platform helps address some of the most significant challenges in brain tumor management," said Michael Schmainda, chief executive of Imaging Biometrics LLC.
Trevor Brown, chief executive of Imaging Biometrics, called it "the second major new installation this quarter, testament to our increasingly relevant software."
News Intelligence what this means for the company
Imaging Biometrics has signed a second major regional US health system to an annual subscription for its quantitative neuro-oncology imaging suite (IB Neuro, IB Delta T1, IB FTBx) in Q3 2026. This follows a similar win with a major academic medical centre in the US Midwest announced in August, signalling traction in a high-value clinical workflow where the company's objective, standardized tumor biomarkers displace subjective MRI interpretation—a material competitive advantage in neuro-oncology treatment decisions.
Two subscription wins in one quarter in the same clinical vertical suggest repeatable demand for quantitative neuro-oncology imaging in the US market. The company reported a swing to profitability (£73,852 PAT in H1 2026) and is now demonstrating recurring revenue traction; however, cash burn remains a constraint (net outflow of £63,226 in H1 2026), so the pace and scale of subscription adoption will determine whether these wins translate to sustainable unit economics.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
